



PAXLOVID™

(Nirmatrelvir tablets (150mg) co-packaged with ritonavir tablets (100mg) for oral use)

Thank you for taking part in the PANORAMIC Trial. Here is some information about the trial treatment you have been given.

The treatment you have been given is called Paxlovid, a new oral (i.e., taken by mouth) antiviral treatment that has been developed specifically for treatment of COVID-19.

The treatment has a conditional license, which means that it has been licensed for use based on less data than normally required. To receive this licence, the data has shown that the treatment's benefits outweigh the risks.

Dose and Administration

Paxlovid consists of 2 medicines: nirmatrelvir tablets co-packaged with ritonavir tablets for oral use.

- Take 2 pink tablets of nirmatrelvir (150mg each) with 1 white tablet of ritonavir (100mg) by mouth 2 times each day (in the morning and in the evening) for 5 days.
 For each dose, take ALL 3 tablets at the same time.
- Swallow the tablets whole, do not chew, break, or crush the tablets.
- Take Paxlovid with or without food.
- If you miss a dose of Paxlovid within 8 hours of the time you would usually take it, then take it as soon as you remember. If it is more than 8 hours of the time that you would usually take your medication, skip the missed dose, and take the next dose at your regular time. Do not take 2 doses of Paxlovid at the same time.
- Please make sure that you complete a five-day course of this treatment, even if symptoms improve and/or you feel better, to reduce the chances of a treatment-resistant version of the virus developing.

Pregnancy Test

Participants of childbearing potential (i.e., participants who are physically able to become pregnant regardless of their current contraception methods or relationship status) must have a negative pregnancy test result prior to starting trial treatment.

- If you are a person of childbearing potential, you will find a urine pregnancy test and instructions on how to perform the test enclosed within your participant pack.
- Please take the pregnancy test as soon as you receive your participant pack, which **must be before** you start the medication.
- If the pregnancy test is negative, please start your medication.
- If the test result is positive, you **MUST NOT** take the medication. Please contact the trial team: 08081 560017.
- A registered nurse/pharmacist or doctor from the trial team will call you on Day 1 (the day after enrolling you into the trial) to confirm that you have received your





participant pack, and (if applicable) taken the pregnancy test, and that the result is negative. If the result is positive, we will withdraw you from the trial and you will be asked to return all medication by a courier arranged by the trial team.

Contraception

If you are of childbearing potential and in a heterosexual relationship, you must use a highly effective form of contraception. Methods of contraception that are acceptable for use with Paxlovid include:

The implant, the coil, male or female sterilisation, the injection, or the progestogen only pill ("the mini-pill") will be acceptable for use with Paxlovid and must be used for the period of 28 days duration of the trial. Paxlovid can stop combined hormonal contraceptives (e.g., "the pill", patch, vaginal ring) from working properly, so if you use a combined hormonal contraceptive, you must use an additional barrier method of contraception for the duration of treatment with Paxlovid and until one full menstrual cycle is completed after the last dose of Paxlovid. However, condoms alone won't be sufficient during the trial. Being abstinent for the 28 days before enrolling in the trial and continuing to be abstinent for the 28-day duration of follow-up will also be acceptable. Abstinence is defined as being in line with your preferred and usual lifestyle. It is important to note that a barrier method on its own is not sufficient.

Pregnancy and breastfeeding

Pregnant and breastfeeding participants will not be eligible.

If you were to become pregnant during the trial you must tell us immediately and you will be withdrawn from the trial, although we will ask to follow you up for safety reasons.

Side-effects

Like all medicines, Paxlovid can cause side effects. Most of these are mild and short-term and not everyone gets them.

Possible side effects of Paxlovid are:

- Liver problems. Please tell your doctor straight away if you have any of these signs and symptoms of liver problems: loss of appetite, yellowing of your skin and the whites of eyes (jaundice), dark-coloured urine, pale coloured stools and itchy skin, stomach are (abdominal pain).
- **Resistance to HIV medicines.** If you have an untreated HIV infection, Paxlovid may lead to some HIV medicines not working as well in the future.

Common side effects include:

- altered sense of taste
- diarrhoea
- high-blood pressure
- muscle aches

Platform Adaptive trial of NOvel antiviRals for eArly treatMent of covid-19 In the Community Paxlovid Participant Card, Version/Date: V1.0 02 March 2022

Professor Christopher Butler IRAS Project number: 1004274 REC Reference number: 21/SC/0393



You will be able to tell us if you are experiencing these and any other side-effects in your daily diary and these will be monitored by a group of medically trained doctors, to ensure your safety. Your GP, a trial doctor or research nurse will also call you on Day 2 (the day after receiving your participant pack and starting your medication) to check whether you have experienced any side-effects since starting your medication.

If you experience side-effects after taking the trial treatment, and you would like to speak to a trial doctor or nurse, please call the 24-hour PANORAMIC Safety telephone line: 0808 168 0130.

Precautions:

Please do not take the treatment if you have:

- have a history of clinically significant allergic reactions to nirmatrelvir or ritonavir or any of the components of Paxlovid
- have severe liver disease characterised by severe ascites, encephalopathy, jaundice, or prolonged INR (increased likelihood of bleeding due to liver disease)
- o have moderate or severe kidney impairment

Please remember that you should not be taking any other medications other than your usual prescribed medication and the treatment you have been given for the trial. If your doctor or pharmacist wants to start a new medicine, stop a medicine you are already taking or change the dose of a medicine you are already taking, you will need to tell them that you are taking Paxlovid as part of the PANORAMIC trial. Your doctor or pharmacist can then contact the PANORAMIC Safety telephone line: 0808 168 0130.

This treatment can cause rare allergic reactions. If you develop any problems, please stop taking the treatment immediately and seek medical advice.

If a medical emergency related to your antiviral treatment occurs while you are at home, you should contact 111, 999, or go to the accident and emergency (A&E) department at your local hospital.

Storage:

Store below 25 °C. Do not refrigerate or freeze.

Medication Return

If you decide that you no longer wish to take the treatment, please let the trial team know either by phone 08081 560017, or email:panoramic@phc.ox.ac.uk. Please confirm when you speak to one of the team, or in your email message, how many tablets will be returned. You will be sent a pre-paid envelope to return the tablets. This will need to be dropped off at a post office as and when it is possible for you (or someone on your behalf) to take it to one. This will allow the return to be tracked.